The US Court ruled that the patent protection period of Lilly lipitai was extended to 2022

Source: Ding Xiangyuan on April 4, 2014, Lilly won a legal judgment in the United States recently, which can prevent its best-selling cancer drug libitum (pemetrexed) generic drug from competing until 2022 The Southern District Court of Indiana ruled that a patent for the use of a vitamin delivery solution for the prevention of libitum side effects was valid and enforceable, rejecting invalid applications filed by several generic manufacturers, including TIWA, Barr and Pliva A combination of vitamin B12 and folic acid taken prior to the use of libitum can reduce treatment-related hematology and gastrointestinal toxicity, and generic manufacturers argue that this use should not be patented In response, Lilly insisted that the discovery was innovative Before this method of limiting toxicity was found, libitum faced the threat of being eliminated in development Lilly has successfully defended its material patents in the United States In addition, an appeal was won in 2012, when the ruling prevented Bitai from competing with generic drugs until 2016, while the pediatric franchise extended it to 2017 Lilly also said that libitum's patent protection in the EU and Japan will expire in 2021 due to its use method patents, although the drug's material patents in these markets will expire next year Link to the original text: http://